Drugs / TBX-3400
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03385486 | Jun 2019 → Feb 2023 | melanoma | Taiga Biotechnologies, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04640246 | Jan 2021 → Jan 2023 | refractory malignant neoplasm | Taiga Biotechnologies, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBX-3400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04640246 ↗ |
| Modality | Cell therapy | “The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.” NCT03385486 ↗ |
| Route | Intravenous | “TBX-3400 by intravenous infusion” NCT03385486 ↗ |